GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Reshape Lifesciences Inc (OTCPK:RSLS) » Definitions » Gross Margin %

Reshape Lifesciences (Reshape Lifesciences) Gross Margin % : 92.94% (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Reshape Lifesciences Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Reshape Lifesciences's Gross Profit for the three months ended in Dec. 2023 was $1.84 Mil. Reshape Lifesciences's Revenue for the three months ended in Dec. 2023 was $1.98 Mil. Therefore, Reshape Lifesciences's Gross Margin % for the quarter that ended in Dec. 2023 was 92.94%.

Warning Sign:

Reshape Lifesciences Inc gross margin has been in long-term decline. The average rate of decline per year is -1.8%.


The historical rank and industry rank for Reshape Lifesciences's Gross Margin % or its related term are showing as below:

RSLS' s Gross Margin % Range Over the Past 10 Years
Min: 41.48   Med: 60.52   Max: 72.98
Current: 63.93


During the past 13 years, the highest Gross Margin % of Reshape Lifesciences was 72.98%. The lowest was 41.48%. And the median was 60.52%.

RSLS's Gross Margin % is ranked better than
66.71% of 796 companies
in the Medical Devices & Instruments industry
Industry Median: 53.575 vs RSLS: 63.93

Reshape Lifesciences had a gross margin of 92.94% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Reshape Lifesciences was -1.80% per year.


Reshape Lifesciences Gross Margin % Historical Data

The historical data trend for Reshape Lifesciences's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reshape Lifesciences Gross Margin % Chart

Reshape Lifesciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 61.67 55.42 61.38 60.52 63.93

Reshape Lifesciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 51.45 53.52 52.97 59.77 92.94

Competitive Comparison of Reshape Lifesciences's Gross Margin %

For the Medical Devices subindustry, Reshape Lifesciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reshape Lifesciences's Gross Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Reshape Lifesciences's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Reshape Lifesciences's Gross Margin % falls into.



Reshape Lifesciences Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Reshape Lifesciences's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=5.5 / 8.678
=(Revenue - Cost of Goods Sold) / Revenue
=(8.678 - 3.13) / 8.678
=63.93 %

Reshape Lifesciences's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=1.8 / 1.982
=(Revenue - Cost of Goods Sold) / Revenue
=(1.982 - 0.14) / 1.982
=92.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Reshape Lifesciences  (OTCPK:RSLS) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Reshape Lifesciences had a gross margin of 92.94% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Reshape Lifesciences Gross Margin % Related Terms

Thank you for viewing the detailed overview of Reshape Lifesciences's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Reshape Lifesciences (Reshape Lifesciences) Business Description

Traded in Other Exchanges
Address
1001 Calle Amanecer, San Clemente, CA, USA, 92673
Reshape Lifesciences Inc is a developer of minimally invasive medical devices to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.
Executives
Thomas Stankovich officer: Chief Financial Officer 1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Barton P. Bandy officer: President and CEO 1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Dan W Gladney director, officer: Chairman, President and CEO 2800 PATTON ROAD, ST. PAUL MN 55113
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Sabby Management, Llc 10 percent owner 115 HIDDEN HILLS DR, SPICEWOOD TX 78669
Arda Phd Minocherhomjee director C/O CHICAGO GROWTH PARTNERS, 303 W MADISON ST., SUITE 2500, CHICAGO IL 60606
Scott P Youngstrom officer: CFO and SVP, Finance 2800 PATTON ROAD ST. PAUL MN 55113
Joseph Patrick Healey 10 percent owner 31 HUDSON YARDS, 10TH FLOOR, NEW YORK NY 10001
Healthcor Partners Ii, L.p. 10 percent owner 152 W. 57TH STREET, 43RD FLOOR NEW YORK NY 10019
Michael Y Mashaal director 309 WAVERLEY OAKS RD., SUITE 105 WALTHAM MA 02452
Healthcor Partners Fund Ii, L.p. 10 percent owner CARNEGIE HILL TOWER 152 WEST 57TH STREET, 43RD FLOOR NEW YORK NY 10019
Jeffrey C Lightcap 10 percent owner 152 W 57TH STREET 43RD FLOOR, NEW YORK NY 10019
Healthcor Partners Management Gp, Llc 10 percent owner 152 W 57TH STREET 43RD FLOOR, NEW YORK NY 10019

Reshape Lifesciences (Reshape Lifesciences) Headlines

From GuruFocus

ReShape Lifesciences to Present at the Q4 Investor Summit

By Value_Insider Value_Insider 11-02-2022

ReShape Lifesciences Announces $750,000 Registered Direct Offering

By Value_Insider Value_Insider 11-08-2022